Antibody and siRNA Nanocarriers to Suppress Wnt Signaling, Tumor Growth, and Lung Metastasis in Triple-Negative Breast Cancer
| Author(s) | Dang, Megan N. | |
| Author(s) | Suri, Sejal | |
| Author(s) | Li, Kejian | |
| Author(s) | Gomez Casas, Carolina | |
| Author(s) | Stigliano, Gianna | |
| Author(s) | Riley, Rachel S. | |
| Author(s) | Scully, Mackenzie A. | |
| Author(s) | Hoover, Elise C. | |
| Author(s) | Aboeleneen, Sara B. | |
| Author(s) | Kramarenko, George C. | |
| Author(s) | Day, Emily S. | |
| Date Accessioned | 2024-06-10T14:55:46Z | |
| Date Available | 2024-06-10T14:55:46Z | |
| Publication Date | 2024-04-26 | |
| Description | This is the peer reviewed version of the following article: M. N. Dang, S. Suri, K. Li, C. Gomez Casas, G. Stigliano, R. S. Riley, M. A. Scully, E. C. Hoover, S. B. Aboeleneen, G. C. Kramarenko, E. S. Day, Antibody and siRNA Nanocarriers to Suppress Wnt Signaling, Tumor Growth, and Lung Metastasis in Triple-Negative Breast Cancer. Adv. Therap. 2024, 2300426. https://doi.org/10.1002/adtp.202300426, which has been published in final form at https://doi.org/10.1002/adtp.202300426. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. © 2024 Wiley-VCH GmbH. This article will be embargoed until 04/26/2025. | |
| Abstract | The paucity of targeted therapies for triple-negative breast cancer (TNBC) causes patients with this aggressive disease to suffer a poor clinical prognosis. A promising target for therapeutic intervention is the Wnt signaling pathway, which is activated in TNBC cells when extracellular Wnt ligands bind overexpressed Frizzled7 (FZD7) transmembrane receptors. This stabilizes intracellular β-catenin proteins that in turn promote transcription of oncogenes that drive tumor growth and metastasis. To suppress Wnt signaling in TNBC cells, this work develops therapeutic nanoparticles (NPs) functionalized with FZD7 antibodies and β-catenin small interfering RNAs (siRNAs). The antibodies enable TNBC cell specific binding and inhibit Wnt signaling by locking FZD7 receptors in a ligand unresponsive state, while the siRNAs suppress β-catenin through RNA interference. Compared to NPs coated with antibodies or siRNAs individually, NPs coated with both agents more potently reduce the expression of several Wnt related genes in TNBC cells, leading to greater inhibition of cell proliferation, migration, and spheroid formation. In two murine models of metastatic TNBC, the dual antibody/siRNA nanocarriers outperformed controls in terms of inhibiting tumor growth, metastasis, and recurrence. These findings demonstrate suppressing Wnt signaling at both the receptor and mRNA levels via antibody/siRNA nanocarriers is a promising approach to combat TNBC. | |
| Sponsor | This work was supported with funding from the National Institutes of Health under award number R01CA211925 and training grant T32GM133395. It was also supported by the National Science Foundation under award DMR1752009. The content is solely the responsibility of the authors and does not necessarily represent the views of the funding agencies. Microscopy equipment used at the Delaware Biotechnology Institute core facility was acquired under a shared instrumentation grant (S10 OD016361) and access was supported by the NIH-NIGMS (P20 GM103446), the NIGMS (P20 GM139760), and the State of Delaware. Histology was supported by the Delaware Center for Musculoskeletal Research (DCMR) COBRE program under NIH-NIGMS award number P20 GM139760. The authors thank C. Riley for assistance with the histological processing and staining for excised organs. | |
| Citation | M. N. Dang, S. Suri, K. Li, C. Gomez Casas, G. Stigliano, R. S. Riley, M. A. Scully, E. C. Hoover, S. B. Aboeleneen, G. C. Kramarenko, E. S. Day, Antibody and siRNA Nanocarriers to Suppress Wnt Signaling, Tumor Growth, and Lung Metastasis in Triple-Negative Breast Cancer. Adv. Therap. 2024, 2300426. https://doi.org/10.1002/adtp.202300426 | |
| ISSN | 2366-3987 | |
| URL | https://udspace.udel.edu/handle/19716/34454 | |
| Language | en_US | |
| Publisher | Advanced Therapeutics | |
| Keywords | gold nanoparticles | |
| Keywords | gene regulation | |
| Keywords | signal cascade interference | |
| Keywords | RNA interference | |
| Keywords | targeted therapy | |
| Keywords | combination therapy | |
| Keywords | lung metastasis | |
| Title | Antibody and siRNA Nanocarriers to Suppress Wnt Signaling, Tumor Growth, and Lung Metastasis in Triple-Negative Breast Cancer | |
| Type | Article |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- Antibody and siRNA Nanocarriers to Suppress Wnt Signaling Tumor Growth and Lung.pdf
- Size:
- 3.28 MB
- Format:
- Adobe Portable Document Format
- Description:
- Main article
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 2.22 KB
- Format:
- Item-specific license agreed upon to submission
- Description: